MedTrace Logo

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

NCT01108809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 295

Last updated 2014-03-28

Study results available
· View outcomes & findings →

Summary

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Conditions

Interventions

DRUG

Telmisartan or Telmisartan and Hydrochlorthiazide

Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-01-31

Countries

  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108809 on ClinicalTrials.gov